Quince Therapeutics, Inc. - Asset Resilience Ratio
Quince Therapeutics, Inc. (QNCX) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Quince Therapeutics, Inc. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Quince Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Quince Therapeutics, Inc..
Liquid Assets Composition Over Time
This chart breaks down Quince Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Quince Therapeutics, Inc. long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Quince Therapeutics, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Quince Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Quince Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Quince Therapeutics, Inc. (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Quince Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.77% | $11.94 Million | $93.52 Million | -17.43pp |
| 2024-12-31 | 30.20% | $34.57 Million | $114.48 Million | +0.06pp |
| 2023-12-31 | 30.14% | $54.31 Million | $180.20 Million | -13.75pp |
| 2022-12-31 | 43.89% | $45.60 Million | $103.91 Million | +16.06pp |
| 2021-12-31 | 27.83% | $37.08 Million | $133.23 Million | -7.52pp |
| 2020-12-31 | 35.35% | $66.98 Million | $189.47 Million | -3.77pp |
| 2019-12-31 | 39.12% | $48.65 Million | $124.37 Million | -25.16pp |
| 2018-12-31 | 64.28% | $46.84 Million | $72.88 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more